After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...